ArticleFrontiers in immunology2022

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.

Xiaoying Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.